¢òzf Retinoic Acid~ ÛB Î"
8
0
0
전체 글
(2) ©ÁêðÂÁÉñx. 534. ¢òzö 'Ëj ~º ¶º F*' º, ¶ F" ?f bÒ' º, melanocyte stimulating hormone(α-MSH), arachidonic acidf &ÒÖb ®b, 6 &æ cytokine &~º ©b rJ^ ® . ¢òzö 'Ëj ~º ¶ 7 &Ë ô rJ ê MSHº α-, β-, x-MSH ^ «~& ®b, * Ú proopiomelanocortin(POMC)b¦V F¾~º ÏW ^Òö ³ . MSHö ~ ¢ò W";f ;{ zî¾ C&ææº p~b¾, ¶Fö ~ 'î;W^ f ¢ò^öB MSH >ÏÚ& Ã& " ÿö b^öB ÖB MSH& ï²^~ ö Ò ~º >ÏÚf Ö . MSHf >ÏÚ~ Ú & ^Ú Ú&B adenylate cyclase¢ WzÎ. . ^Ú cyclic adenosine monophosphate(cAMP)¢ Ã&B protein kinase A(PKA)f tyrosinase& W z>, tyrosinaseö ~ ¢ò W>º ©b B : ® . Lernerf McGurie & Úb¦~ ¢òzf MSH f~ &Wj B~& . Fullerf Meyskens º V ·B Ú ¢ò^f kW wï«^"ö α-MSH ¢ Î&~ tyrosinase~ Wê¢ &V~& . Halaban " Ranson f V·B Ú ¢ò^öB α-MSH~ >ÏÚf α-MSH~ >ÏÚ¢ BÒ~&b , Donation f α-MSH& Ú ¢ò^öB ^Ú ã*bî cAMP~ ·" tyrosinase~ Wê¢ Ã&ʺ ©j ~& . Þ, jæ" A W FêÚ all-trans-retinoic acid (RA)º b~ 'î^öB ¢ò^¢ ªÖB ï ²Oj vÒ² ~, ï²^~ >æçòVöB ' î^~ ï²*j O~, bvÚ¢ &³B ﲶ j /ê~º ©b B : ® . ß®, RAº b¦& ¶Fö  >Ú ¾æ¾º "ï²O ~ .O" ~òö Î"¢ "º ©b rJ^ ® . ¾ Zheng" Kligman f Yucatan pig~ b¦ ö RA¢ ê~ ¢ò^~ >f V& Ã&~ ¢ò W /êB º Ö"¢ ~&, Yaarf Gilchrest º V·B Ú ¢ò^öB RA º ¢ò ·¾ tyrosinase~ Wêö 'Ëj "æ pº ~&b, Romero f tyrosinase Wê ¢ ÛB ~& . Garbe f Orlow f wï 2. 3. 4. 5-8. 9. 10. 11. 12. « ^~ V· þ Ö" RAº ¢ò^~ Ãj ÛB~¾ ªz¢ /ê~B ¶Fö Â>æ p f öB F~ ¢ò Wj /ê~¾, ¶Fö ÂB çöB ^Ò¾ £bö ~ &'b Fê>º ª~~ ¢ò Wf ÛB ~& . f ? ¢ò^f wï« ^ ÒöB, 6º « ÒöBê ^~ à 5 ¢òzö & RA~ 'Ë B ç>>² ¾æ¾º ©b > îj ö, ¢òzö &NB >wãf RA~ 'Ëö &Bº jçræ ;{® C&^ ®æ p . r·#(Epimedium koreanum Nakai: EK)f âæ #.~ æ禢 ©, OöBº ;Ë, ;;B 5 r*~òB n®® ¾O, R£> ®b "öº >&~ Ëçb ²j& Ã& º^ ö ®º 7º £ . r·#~ "Wªf flavonoid icariin, epimedo side A b C&rb , 7 icariinf .{ö Î"¢ ¾æÚº ©b >î . öBº r·# ¢ò^~ ¢òzö & ~º ©" ¢ò W~ >wã zî¾ö ~ º 'Ëj «~V *~, r·# bºÂ" αMSHö ~ ¢ò W 5 tyrosinase Wê¢ Ò~&b, B16 melanoma ^~ ¢òzö & RA~ 'Ëj Ò~ jv~& . 21. 22-25. 13. 14. 15. 16. 17. 18. 19. 20. þ. £Ò ºÂ. £Ò r·# 400 gö 3NÃ~> ¢ &~ 3 * ÿn yB ª« " ~& . 3,200 rpmb 30 ª* öªÒ ê −70 CöB freeze dryer ïÿ, B 42.75 g~ ò ¢ áî . òº Dulbecco's Modified Eagle Medium (DMEM, Gibco. Co., USA) V·ö ê ^ ö R~V * 0.22 µm "æ "~ ~ ³ê¢ ; r ÒÏ~& . £B. α-MSH(Sigma, USA)º 0.5 M acetic acidö stock solutionb ò ê DMEM V ·b C~ ïËö &~B ÒÏ~& . RA(Sigma)º EtOHö &ËÏj ò Ú ïz² ö &~B ÒÏ~& . SRB assay. Sulforhodamine B(SRB) assayº Skelan ~ O»j æ;~ G;~& . 96 well V·ÏVö 6.5 L o. 26. Journal of the Korean Chemical Society.
(3) r·#" α-MSHö ~ B16 Melanoma ^~ ¢òzf Retinoic Acid~ ÛB Î". ^"f¯ : KCLB)¢ well 1 Ü10 B& >ê V·~& . ' wellö 4 C~ 50% trichloroacetic acid(TCA) Ï 50 µL¢ Ê#² Î&~ 1* ÿn 4 CöB &~ V·ÏV~ ^ j ;~& . ¢ vº b 5² af ê. NöB V . Vö 1% .Öö 0.4% SRB(Sigma Co., U.S.A.)¢ I 30ª ÿn O~ ê SRB¢ B~ 1% .Öb 4² a ¢. NöB Î ê 10 mM unbuffered tris base (pH 10.5)¢ Î&~& . NöB 10ª* O~. r enzyme linked immunosor-bent assay(ELISA) reader¢ Ï~ 490 nmöB 7ê¢ G;~& . ¢ò · G;. ¢ò ·f Hosoi ~ O»j æ;~ ÒÏ~& . ^¢ V·~ phosphate buffered saline(PBS) 2² ^¿ ê öªÒ~ ^ *bj ò î . 10% dimethyl sulfoxide (DMSO)& Î&B 1 N NaOH Ïj 200 µL Î&~ 80 CöB 1* ÿn Ï~& . 405 nmöB 7ê¢ G;~&b, ¢ò ·f W ¢ò(Sigma Co., USA)j ÒÏ~ ·WB & çFöB ~,. þ~ ¢ò ·f &~ ¢ò ·ö & W ªN êÖ~& . Tyrosinase Wê G;. Matinez-Esparza ~ O »ö ~~ G;~& . ' wellöB ¢ò ^¢ > {~ öªÒ ê ^ *bj ò î . 100 µL ^Ï(1% Triton X-100, 10 mM sodium phosphate, 0.1 mM phenyl methyl sulfonyl fluoride)j I ârö O~~ ^¢ 2ZÎ ê öªÒ ~&, ç[j ~ βÏb ÒÏ~& . 100 mM sodium phosphate(pH 7.0) Ï 100 µLö ò β Ï 50 µL¢ I 37 CöB 5ª* N ê 100 mM catechol 50 µL¢ &~& . ELISA reader 37 C, 405 nmöB 7ê~ æz¢ 1* ÿn &V~& . ÛêO». þÖ"º ïÛ&ÞN ~&b , ' þj &ö & WªN ¾æÚî . ' *~ Ûê' F~Wö & ¦Ãf Student’s ttest¢ ÒÏ~, p-value& 0.05 ò¢ r Ûê'b F~W ® 6;~& . B16 melanoma( 5. o. o. 27. o. 28. 535. ^~ Nö ÚÊ 'Ëj ~º&¢ rjV *~ r·# bºÂj 1 µg/mLöB 200 µg/mLræ~ · ³ê B16 melanoma ^ö ¾Ò~ 72 * êö SRB O»b ^~ N j &V~& . Fig. 1öB º :f ? r·# b ºÂö ~ ^~ Nöº æz¢ ¾æÚæ p~b¾ 200 µg/mL~ ³êöBº £ 5%~ 6²¢ & . ¢ò Wö ~º 'Ë. ÚÚöB~ melanin W";f b& tyrosinej Vî ~ L-3,4dihydroxyphenylalaninej WÊ ¢ Ldopaquinoneb *ʺ ³B β' Öz& ê ¯B ê ' Wb~ 7 >w ö ~ Úê. . α-MSHº ÚÚ ¢ò Wö ®ÚB &Ë 7 º bî ò~>ÚöB ªj>, 3-isobutyl-1melanoma. methylxanthine(IBMX), forskolin, dibutyryl cAMP(dbc. f îR&æ cAMP ~; ^* ã PKA ã ¢òz¢ /ê . α-MSHf r·# bºÂ B16 melanoma ^ ~ ¢òzö ~º 'Ëj rjV *~, B16 melanoma ^¢ well 1×10 BO I 24* ã" ê îÚ V·b vÚ r. · ³ê~ α-MSHf r·# bºÂj &~ 72* V· r ¢ò ·j G;~ jv~&. . b& α-MSH& ¢ò Wö ~º 'Ëj Fig. 2AöB º :f ? α-MSH ¾Ò f &ö j~ Îv Ûê'b F~W ®º Ã&¢ &b(p<0.05f p<0.01), ß® 8 ng/mLö Bº &ö j~ £ 2.5 V~ ¢ò W à AMP). 29. 5. o. o. Ö" 5 V ^Nö ~º 'Ë. r·#~ ºÂb B16 2000, Vol. 44, No. 6. Fig. 1. Effect of the aqueous extract of Epimedium koreanum NaKai (EK) on the viability of B16 melanoma cells. The cells were treated with various concentrations of EK for 72 hrs. The viability of the cells was measured by SRB assay..
(4) ©ÁêðÂÁÉñx. 536. ";~ "B β tyrosinaseº ¾¦zbj Vî Ï~º Ò F polyphenol oxidase β . Tyrosinaseº ÚÚöB monophenol tyrosinej DOPA (o-diphenol) Özʺ tyrosine oxidase B~ VË" DOPA¢ DOPA quinone(o-quinone)b Özʺ dopa oxidaseB~ VËj <º . Ú ÚöB~ VË r^ö tyrosinaseº ¢ò polymer¢ W~º 7º j ~ ®, V ¢B ¢ò^öB~ tyrosinase Wf b¦ ¢ò Wö Ö;'b 'Ëj ~² B . α-MSH ¾Ò~ 48* V· ê tyrosinase~ Wê¢ G;~& . Fig. 3AöB º :f ? α-MSH ¾Ò & 31. Fig. 2. Change in melanin contents according to treatment of α-MSH and EK on B16 melanoma cells. After treatment for 72 hrs, melanin contents was measured at 405 nm. Data were the mean±S.D. This experiment was repeated five times. A: α-MSH (*p<0.01, **p<0.001), B: EK (*p<0.01).. &¢ & . ©f ; 8 ng/mL α-MSH¢ ¾Ò~ 2.6V~ ¢ò Ã&¢ áf Ö"f ¾ ¢ ~~& . r·# bºÂ ¢ò Wö ~º 'Ëj r V *~ r·# bºÂj 1 µg/mLöB¦V 200 µg/mLræ ·~² ¾Ò ê 72* V· r B16 melanoma ^~ *Ú ¢ò ·j G; Ö "º Fig. 2Bf ? . α-MSH~ ãÖ Ã& ·~æò, r·# bºÂ~ · Ã&ö V¢ & ö j~ þ Îv Ûê'b F~W ®² Ã&~& (p<0.05f p<0.01), ß® 100 µg/mL r· # ¾ÒöBº &ö j~ £ 1.6V~ ¢ò W Ã&¢ & . Tyrosinase Wêö ~º 'Ë. ¢ò W 30. Fig. 3. Change in tyrosinase activity according to treatment of α-MSH and EK on B16 melanoma cells. After treatment for 48 hrs, tyrosinase activity was measured at 405 nm. Data were the mean±S.D. This experiment was repeated five times. A: α-MSH (*p<0.05), B: EK (*p<0.05). Journal of the Korean Chemical Society.
(5) r·#" α-MSHö ~ B16 Melanoma ^~ ¢òzf Retinoic Acid~ ÛB Î". ö j~ Îv Ûê'b F~W ®² Ã&>î b, ß® 8 ng/mLöBº &ö j~ £ 3.6 V~ tyrosinase Wj & (p<0.05). ©f Fig. 2A~ ¢ò · 2.5V Ã& ©" jv~ z ô f Ã&Nj © . r·# bºÂj 1 µg/mLöB¦V 200 µg/mLr æ ê'b Î&~ 48* V· r tyrosinase Wê¢ G; Ö"¢ Fig. 3Bö & . r ·# bºÂ~ Î& · Ã&ö V¢ &ö j~ þöB Îv Ûê'b F~W ®² Ã& ~&, ß® 100 µg/mL RöBº &ö j~ £ 2V~ Ã&¢ & (p<0.05). α-MSHf r·# bºÂj '' B16 melanoma ^ö ¾Ò &ö j~ ¢ò ·" tyrosinase W Îv Ã&~º ãËj &, Ã& ~º ·ç B jÝ~& . ©f α-MSHf îR &æ r·# bºÂê B16 melanoma ^ö ¾ Ò melanoma ^~ ¢òz¢ ¶ ~ tyrosinase & Wz>Ú ¢òz& /ê>º ©b ÒòB . α-MSHf r·# bºÂj ¾Ò ~ tyrosinase W" Fig. 2~ ¢ò ·j jv" r tyrosinase W ¢ò ·ö j~ z ôf Ã&¢ &º, ©f α-MSHf r·# bºÂj B16 melanoma ^ö ¾Òb ¢ò W~ .V êöB tyrosinase~ W Ã&~æò, ê~ >wã j ~º ÿnö «Öb ¢ò~ W>N ÔjæV r^¢ © . RA& F ¢òzö ~º 'Ë. &~ ¢ ò ·" tyrosinase Wê¢ G;~ B16 melanoma ^~ F ¢òz¢ Ò~&, þj RA~ ³êê ¾Ò~ ¢ò ·" tyrosinase Wê¢ G ;~ jv~¢ Fig. 4Aö & . Fig. 4AöB º :f ? &ö j RA ¾Ò þ öB ¢ò W~ ÛB Î"¢ & b, RA 1 µM ³êöB &Ë ÛB Î"(26 %)¢ & . Tyrosinase Wêö ~º 'Ëf Fig. 4BöB º :f ? 1Ü10 µMöBº ÛB Î"& ~ ìb¾ RA~ ³ê& Ã&> tyrosinase~ Wê & ² ÛB>îb, 10 µM ³êöB &ö j 44%~ ÛB Î"¢ & . RA ¾Òö V¢ ¢ò ·" tyrosinase W Î −3. 2000, Vol. 44, No. 6. 537. Fig. 4. Effect of RA concentraion on melanin contents and tyrosinase activity of B16 melanoma cells. Melanin was measured from cultured cells for 72 hr. Data were the mean±S.D. This experiment was repeated five times. A: αMSH (*p<0.05), B: EK (*p<0.05).. v 6²Nö V¢ RA& B16 melanoma ^~ ¢ òzö ç7 &~ ^~ ¢òz¢ ÛBÚj r > ®îb, ¢ò º tyrosinase Wj *& ® &~V . α-MSHf r·# bºÂö ~ ¢ò Wö ~º RA~ 'Ë. ¦¶ ö ~ B16 melanoma ^~ ¢òzö ~º RA~ 'Ëj &V~V * ~ α-MSHf r·# bºÂb ¶ " ÿö RA¢ ³êê R~ ¶ ö ~ ¢òzö ~º RA~ 'Ëj &V~& . Fig. 2AöB ¢ò W &Ë ¸² ¾æ 8 ng/ mL α-MSH B16 melanoma ^¢ ¾Ò~,. RA¢ ³êê ¾Ò r 72* V· ê ¢ò ·j G;~ Fig. 5Aö & ..
(6) 538. ©ÁêðÂÁÉñx. Fig. 5. Change in melanin contents according to concentration of RA in a given α-MSH and EK treatment on B16 melanoma cells. The cells were seeded at 1×105 cells/well. After treatment of RA for 72 hrs, melanin contents was measured at 405 nm. Data were the mean±S.D. This experiment was repeated five times. A: 8 ng/mL α-MSH+RA (*p<0.05), B: 100 µg/mL EK+RA (*p<0.05).. öB º :f ? RA ³ê Ã&ö V¢ ö ~ ¢ò ·j ÛB~º Î"¢ ¾æÚ î ÛB ;êº 40% n4~ ÛB Î"¢ ¾æÚî b 0.01 M RA ³êöB 54%~ &Ë ÛB Î "¢ & . Fig. 2BöB ¢ò W &Ë ¸² ¾æ 100 µg/mL r·#j B16 melanoma ^ö ¾Ò~, ³ êê RA¢ ¾Ò r 72* V· ê ¢ò ·j G;~ Fig. 5Bö & . Fig. 5BöB º :f ? r·#ö ~ B16 melanoma ^~ ¢òzö & RA~ 'Ëf RA Fig. 5A. α-MSH. ³êö V¢ ¢ò ·j ÛB~º Î"¢ ¾æÚî. . ÛB ;êº α-MSHf îR&æ 40% ;ê~ ÛB¢ & 1 µM RA ³êöB 50% &Ë ÛB Î"¢ & . α-MSHf r·# bºÂö ~ tyrosinase W ö ~º RA~ 'Ë. Tyrosinase Wö ~º RA~ 'Ëj Ò~V *~ 8 ng/mL α-MSH ¾ Ò B16 melanoma ^ö RA¢ ³êê ¾Ò ê tyrosinase Wê¢ G; Ö"¢ Fig. 6Aö & . Fig. 6AöB º :f ? RA& ÛB·Ïj ~ α-MSHö ~ tyrosinase~ Wj Ûê'b. Fig. 6. Change in tyrosinase activity according to concentration of RA in a given α-MSH and EK treatment on B16 melanoma cells. After treatment of RA for 48 hrs, tyrosinase activity was measured at 405 nm. Data were the mean±S.D. This experiment was repeated five times. A: 8 ng/mL α-MSH+RA (*p<0.05, **p<0.001). B: 100 µg/mL EK+RA (*p<0.05). Journal of the Korean Chemical Society.
(7) r·#" α-MSHö ~ B16 Melanoma ^~ ¢òzf Retinoic Acid~ ÛB Î". 539. r·#f 100 µg/mL ¾Ò ^N 95% çb ¶Ú ^ëW Î"º ~ ¾æ¾æ p~ . 2) α-MSHf r·# Îv tyrosinase activity¢ à &V . 3) α-MSHf r·# Îv «Öb ¢ò ·~ Wj /êV . 4) RAº B16 melanoma~ ¢òzf tyrosinase Wj ÛBV . ç~ Ö"öB α-MSHf r·#b melanoma ^¢ ¾Ò ãÖö ¢ò W 5 tyrosinase Wê& ~ jÝ~² Ã&>îb, RA~ ¾Òö ~ Bº jÝ 6²¢ º ©b j r·#ö ~ ¢òzº v-MSHf îR&æ cAMP ^ * ã¢ Û /ê>º ©b C>î . 1). Scheme 1. Intracellular signal transduction pathway in melanogenesis. I: PKA pathway (proposed EK mechanism), II: PKC pathway.. F~W ®² 6²Vb¾(p<0.05 _f p<0.01), 100 r·# bºÂb ¾Ò B16 melanoma ^ö RA¢ ³êê ¾Ò~ 48* V· ê tyrosinase Wê¢ G; Ö"º Fig. 6Bf ? . r·#b ¾Ò~æ jî B16 melanoma ^öB f îR&æ r·#b ¾Ò öBê RA ¾Ò ö V¢ tyrosinase W Îv 6²>º ©b ¾ æÒb(p<0.05), 10 M~ RAöBº &~ 100% ~ræ 6²>î . RAº α-MSH¾ r·# ¾Ò~ FZö &ê ì ¢òz¢ ÛB~º ©b ÒòB . ÿ¢ ³ê~ RAö ~ ÛB ;ê& α-MSHf r·#b ¾Ò öB z ² ¾æ ©b " r ¢ò^~ "ï²¢ º ÷æöB RA~ ÛB Î"& z ® j ©b V&B . α-MSHf r·# ¾Òö ~ ¢ò W 5 tyrosinase Wê& ~ jÝ ãËj º ©b j r·# bºÂö ~ B16 melanoma ^ ~ ¢òzº α-MSH~ ãÖf îR&æ cAMP ~; ^ *ã PKA ãf &N ®bÒ ¢ º;>, Imokawa ~ α-MSH zî¾j ^~ r·# b ºÂ~ ¢òz ";~ zî ¾f Scheme 1" ? Bn > ® . µg/mL. 32. Ö. . öBº r·#ö ~ ¢ò W~ ^* zî¾j «~V *~ r·# ¢òï² ;Wö ~º 'Ëj rj α-MSHf r·#ö ~ ¢ò Wj jv~&b, α-MSHf r·#ö ~ ¢òzö ~º RA~ 'Ëj Ò~& . 2000, Vol. 44, No. 6. º BK 21 Òë~ j æöb >¯> îb &¶ 7 f¢7f "Òæ; ö7& v ~£¶öbV 5 *¢§ê êÓ~ jæö ö 6Òãî .. Ï^ò 1. Pawelek, J. M.; K rner, A. M. Am. Sci. 1982, 70, 136. 2. Bolognia, J. J. Invest. Dermatol. 1989, 92, 651. 3. Gilchrest, B. A.; Park, H. Y.; Eller, M. S. Photochem. Photobiol. 1996, 63, 1. 4. Chakraborty, A.; Slominski, A.; Ermak, G. J. Invest. Dermatol. 1995, 105, 655. 5. Im, S.; Moro, O.; Peng, F. Cancer Res. 1998, 58, 47. 6. Luger, T. A.; Scholzen, T.; Grabbe, S. Invest. Dermatol. Symp. Proc. 1997, 2, 87. 7. Hadley, M. E. Source Synthesis, Chemistry, Secretion and Metabolism in the Melanotropic Peptides; Vol 1, CRC Press Boca, Raton FL, 1988. 8. Jose, H. J. Invest. Dermatol. 1992, 99, 435. 9. Lerner, A. B.; McGuire, J. S. Nature. 1961, 189, 176. 10. Fuller, B. B.; Meyskens, F. L. Jr. J. Natl. Cancer Inst. 1981, 66, 799. 11. Halaban, R.; Ponerantz, S. H.; Marshall, S. J. Cell Biol. 1983, 97, 480. 12. Ranson, M.; Posen, S.; Mason, R. S. J. Invest. Dermatol. 1988, 91, 593. 13. Donation, P. D.; Hunt, G.; Pieron, C. Arch. Dermatol. Res. 1992, 284, 424. 14. Kligman, L. H. J. Am. Acad. Dermatol. 1986, 15, 779. 15. Kligman, A. M.; Willis, I. Arch. Dermatol. 1975, 111,.
(8) r·#" α-MSHö ~ B16 Melanoma ^~ ¢òzf Retinoic Acid~ ÛB Î" 40. 16. Zheng, P.; Kligman, A. M. J. Invest. Dermatol. 1991, 96, 576. 17. Yarr, M.; Gilchrest, B. A. J. Invest. Dermatol. 1991, 97, 611. 18. Romero, C.; Aberdam, E.; Larnier, C. J. Cell Sci. 1994, 107, 1095. 19. Garbe, C.; Krasagakis, K.; Kruger, S. J. Invest. Dermatol. 1991, 96, 1000. 20. Orlow, S. J.; Chakraborty, A. K.; Pawelek, J. M. J. Invest. Dermatol. 1990, 94, 461. 21. Shin, K. H.; Lim, S. S. Kor. J. Medicinal Crop. Sci. 1996, 4(4), 321. 22. Kang, S. S.; Shin, K. H.; Chung, S. G.; Cho, E. H. Kor. J. Pharmacogn. 1988, 19(2), 93. 23. Xu, G. W.; Xu, B. J.; Wang, M. T. Chin. Pharm. Bull.. 2000, Vol. 44, No. 6. 540. 1987, 22, 129. 24. Xu, S. C.; Wang, Z. X.; Wu, L. J.; Wang, N. B.; Chen, Y. J. Chin. Trad. Herb Drugs. 1982, 13, 9. 25. Miyase, T.; Ueno, A.; Takizawa, N.; Kobayashi, H.; Oguchi, H. Chem. Pharm. Bull. 1987, 35, 3713. 26. Skelan, P.; Storeng, R. J. Natl. Cancer Inst. 1990, 82, 1107. 27. Hosoi, J.; Abe, E.; Suda, T.; Kuroki, T. Cancer Res. 1985, 45, 1474. 28. Matinez-Esparza, M. Eur. J. Biochem. 1998, 225, 139. 29. Bryan, B. F. J. Invest. Dermatol. 2000, 114(2), 268. 30. Park, J. S.; Nam, W. Y.; Mun, Y. J.; Jeon, B. H.; Woo, W. H. Kor. J. Orient. Med. Pathol. 2000, 14(1), 160. 31. Vamons-Vigyazo, L. CRC Crit. Rev. Food Sci. Nutr. 1981, 15, 49. 32. Imokawa G. T. Pigment Cell Res. 1997, 10, 218..
(9)
관련 문서
Basic aspects of AUTOSAR architecture and methodology Safety mechanisms supported by AUTOSAR.. Technical safety concepts supported by AUTOSAR Relationship to ISO
GDP impact of COVID-19 spread, public health response, and economic policies. Virus spread and public
Micro- and nano-sized pores were formed on the surface of the alloy using PEO and anodization methods, and the pore shape change according to the Zr
Department of Japanese Language and Literature, Graduate School, Cheju National University. Supervised by Professor
The melanoma cell line WM793 was employed for the Fascin and MST2 knock-down and then analyzed by the Western blot assay, and the melanoma xenograft followed by Fascin
Inhibitory effects of classified methanol extracts of Smilax china L on the COX-2 and iNOS expression of human colorectal cancer cell lines... Inhibitory
Dombret H, Sutton L, Duarte M, Daniel MT, Leblond V, Castaigne S, Degos L: Combined therapy with all-trans retinoic acid and high-dose chemotherapy in
Currently, the method of radioactive strontium( 90 Sr) analysis uses the nitric acid method and resin method.. The act of nitric acid method and
